These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25924799)

  • 21. Pulmonary arterial hypertension: a current review of pharmacological management.
    Sahni S; Ojrzanowski M; Majewski S; Talwar A
    Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Riociguat for the treatment of pulmonary hypertension.
    Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
    Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pulmonary hypertension: definition, classification and treatments].
    Jutant EM; Humbert M
    Biol Aujourdhui; 2016; 210(2):53-64. PubMed ID: 27687597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fixed-dose combination therapy in pulmonary arterial hypertension: Pros & cons.
    Manzi G; Recchioni T; Badagliacca R; Papa S; Vizza CD
    Int J Cardiol; 2024 Jul; 406():132003. PubMed ID: 38561109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Targeted therapy of pulmonary arterial hypertension (PAH)].
    Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel strategies for treatment of pulmonary arterial hypertension.
    Jasińska-Stroschein M; Orszulak-Michalak D
    Postepy Hig Med Dosw (Online); 2017 Jul; 71(0):577-588. PubMed ID: 28791952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ESC guidelines 2015 on pulmonary hypertension].
    Olschewski H; Kovacs G; ;
    Herz; 2015 Dec; 40(8):1055-60. PubMed ID: 26626554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
    Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
    Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.
    Bishop BM; Mauro VF; Khouri SJ
    Pharmacotherapy; 2012 Sep; 32(9):838-55. PubMed ID: 22806762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and advancing treatments for pulmonary arterial hypertension in childhood.
    Zijlstra WM; Ploegstra MJ; Berger RM
    Expert Rev Respir Med; 2014 Oct; 8(5):615-28. PubMed ID: 25047735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
    Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
    Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
    Lasker GF; Maley JH; Pankey EA; Kadowitz PJ
    Expert Rev Respir Med; 2011 Apr; 5(2):153-61. PubMed ID: 21510726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of Pulmonary Arterial Hypertension].
    Klose H; Harbaum L; Oqueka T; Simon M; Grünig E
    Pneumologie; 2015 Aug; 69(8):483-93; quiz 494-5. PubMed ID: 26220551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eisenmenger syndrome: recent advances in pharmacotherapy.
    Said S; Porres-Aguilar M; Porres-Munoz M; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):289-96. PubMed ID: 24655213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
    Hansmann G; Apitz C
    Heart; 2016 May; 102 Suppl 2():ii67-85. PubMed ID: 27053700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
    Yao A
    J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological treatment of HIV-associated pulmonary hypertension.
    Chinello P; Petrosillo N
    Expert Rev Clin Pharmacol; 2016; 9(5):715-25. PubMed ID: 26863919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.